RPL23

Across TCGA pan-cancer cohorts, RPL23 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RPL23 data layer compared with 26 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher RPL23 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RPL23 expression acts as an unfavorable survival marker.

STAD, LUSC, and SKCM are the cancer types where RPL23 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.221	0.689	.001	24	view →
LUSC	OS	Median	All	0.011	0.819	<.001	9	view →
SKCM	OS	Median	All	0.299	0.781	.031	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RPL23–STAD (OS)

Open the STAD breakdown →